CD8A and neoplasm: Thus, the increase of CX3CR1+CD8+ T cells within the spleen during T cell priming in the presence of ICI therapy may correlate with an increased migratory capacity of effector CD8+ T cells eventually facilitating their enrichment at tumor sites to cause tumor regression.